Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Increases By 585.0%

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 13,700 shares, a growth of 585.0% from the March 15th total of 2,000 shares. Based on an average daily volume of 25,700 shares, the short-interest ratio is presently 0.5 days.

SAB Biotherapeutics Price Performance

SABSW stock traded down $0.00 during mid-day trading on Tuesday, reaching $0.02. 1,052 shares of the stock traded hands, compared to its average volume of 22,716. SAB Biotherapeutics has a 52-week low of $0.01 and a 52-week high of $0.18. The stock’s fifty day moving average is $0.03 and its 200-day moving average is $0.05.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.